Olav Dalgard

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi request reprint Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    Olav Dalgard
    Department of Medicine, Aker University Hospital, Oslo, Norway
    Hepatology 40:1260-5. 2004
  2. ncbi request reprint Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    Olav Dalgard
    Infectious Disease Department, Ulleval University Hospital, Oslo, Norway
    Hepatology 47:35-42. 2008
  3. doi request reprint IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Amir Moghaddam
    Furst Medisinsk Laboratorium, Oslo, Norway
    Hepatology 53:746-54. 2011
  4. ncbi request reprint Follow-up studies of treatment for hepatitis C virus infection among injection drug users
    Olav Dalgard
    Unit of Hepatology, Aker University Hospital, Oslo, Norway
    Clin Infect Dis 40:S336-8. 2005
  5. ncbi request reprint Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection
    Olav Dalgard
    Department of Microbiology Ullevål University Hospital, Oslo, Norway
    Drugs 66:1807-15. 2006
  6. doi request reprint In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials
    Olav Dalgard
    Medical Department, Rikshospitalet, Oslo
    Eur J Gastroenterol Hepatol 22:552-6. 2010
  7. doi request reprint [Risk factors for hepatitis C among injecting drug users in Oslo]
    Olav Dalgard
    Medisinsk avdeling Rikshospitalet 0027 Oslo
    Tidsskr Nor Laegeforen 129:101-4. 2009
  8. doi request reprint Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
    Håvard Midgard
    Department of Gastroenterology, Aker University Hospital, Oslo, Norway
    Scand J Gastroenterol 45:1503-8. 2010
  9. ncbi request reprint Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection
    Olav Dalgard
    Medical Department Aker University Hospital, Oslo, Norway
    Hepatology 39:74-80. 2004
  10. doi request reprint Short treatment to patients with genotype 2 or 3
    Olav Dalgard
    Hepatology 48:694. 2008

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    Olav Dalgard
    Department of Medicine, Aker University Hospital, Oslo, Norway
    Hepatology 40:1260-5. 2004
    ..The results need to be confirmed in a randomized, controlled study before this treatment approach can be recommended, particularly for patients with genotype 3 and high viral load or severe fibrosis...
  2. ncbi request reprint Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    Olav Dalgard
    Infectious Disease Department, Ulleval University Hospital, Oslo, Norway
    Hepatology 47:35-42. 2008
    ....
  3. doi request reprint IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Amir Moghaddam
    Furst Medisinsk Laboratorium, Oslo, Norway
    Hepatology 53:746-54. 2011
    ..018; rs8099917, not significant) and high alanine aminotransferase (ALT, rs12979860, P = 0.002; rs8099917, P = 0.001), in addition to a high baseline viral load (rs12979860, P = 1.4 × 10(-5) ; rs8099917, P = 7.3 × 10(-6) )...
  4. ncbi request reprint Follow-up studies of treatment for hepatitis C virus infection among injection drug users
    Olav Dalgard
    Unit of Hepatology, Aker University Hospital, Oslo, Norway
    Clin Infect Dis 40:S336-8. 2005
    ..It has not been determined whether any of these cases were actual reinfections. Available data suggest that the rate of long-term response to treatment for HCV infection is excellent in IDUs...
  5. ncbi request reprint Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection
    Olav Dalgard
    Department of Microbiology Ullevål University Hospital, Oslo, Norway
    Drugs 66:1807-15. 2006
    ..For patients with genotype 3, a univocal recommendation on treatment duration cannot be made. However, ongoing trials will probably clarify this aspect...
  6. doi request reprint In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials
    Olav Dalgard
    Medical Department, Rikshospitalet, Oslo
    Eur J Gastroenterol Hepatol 22:552-6. 2010
    ..To compare 14 and 24 weeks treatment to patients with HCV genotype 2 or 3 infection and rapid virological response (RVR)...
  7. doi request reprint [Risk factors for hepatitis C among injecting drug users in Oslo]
    Olav Dalgard
    Medisinsk avdeling Rikshospitalet 0027 Oslo
    Tidsskr Nor Laegeforen 129:101-4. 2009
    ..Hepatitis C virus (HCV) infection is common among injecting drug users. The aims of this study were to assess the prevalence of risk behaviour and its association with HCV infection...
  8. doi request reprint Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
    Håvard Midgard
    Department of Gastroenterology, Aker University Hospital, Oslo, Norway
    Scand J Gastroenterol 45:1503-8. 2010
    ..The aim of this study was to examine the significance of native country for the stage of liver fibrosis in a population of HCV patients of Pakistani or Scandinavian origin living in Oslo...
  9. ncbi request reprint Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection
    Olav Dalgard
    Medical Department Aker University Hospital, Oslo, Norway
    Hepatology 39:74-80. 2004
    ..In conclusion, chronic HCV infection per se did not negatively affect the HRQOL of active injecting drug users. Those who thought they were infected had a lower HRQOL scores than those who believed they were not infected...
  10. doi request reprint Short treatment to patients with genotype 2 or 3
    Olav Dalgard
    Hepatology 48:694. 2008
  11. ncbi request reprint [Hepatitis C--a health problem also in Norway]
    Inger Sofie Samdal Vik
    Avdeling for virologi Nasjonalt folkehelseinstitutt Geitmyrsveien 75 0462 Oslo
    Tidsskr Nor Laegeforen 128:563-6. 2008
    ..The aim of this article is to describe the clinical course, microbiological diagnostic approaches, therapy, prophylaxis and public health aspects of Hepatitis C infection...
  12. ncbi request reprint [Treatment of chronic hepatitis C]
    Helge Bell
    Seksjon for leversykdommer Medisinsk klinikk Aker universitetssykehus 0514 Oslo
    Tidsskr Nor Laegeforen 122:926-8. 2002